Who are Combination of pimecrolimus and fluticasone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-of-pimecrolimus-and-fluticasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Combination of pimecrolimus and fluticasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of pimecrolimus and fluticasone (Combination of pimecrolimus and fluticasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical immunosuppressant and corticosteroid combination. Area: Dermatology/Immunology.

marketed Topical immunosuppressant and corticosteroid combination Calcineurin (pimecrolimus); glucocorticoid receptor (fluticasone) Dermatology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Combination of pimecrolimus and fluticasone (Combination of pimecrolimus and fluticasone) — Children's Hospital of Philadelphia. This combination suppresses skin inflammation by blocking T-cell activation (pimecrolimus) and reducing inflammatory mediator production (fluticasone).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combination of pimecrolimus and fluticasone TARGET	Combination of pimecrolimus and fluticasone	Children's Hospital of Philadelphia	marketed	Topical immunosuppressant and corticosteroid combination	Calcineurin (pimecrolimus); glucocorticoid receptor (fluticasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical immunosuppressant and corticosteroid combination class)

Children's Hospital of Philadelphia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Combination of pimecrolimus and fluticasone — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-of-pimecrolimus-and-fluticasone. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab